Genocea Biosciences Inc (GNCAQ)

[jondoeuk]

They use high-dose IL-2.

[NY1972]

Did IOVA use intermediate dose IL-2 post ACT in their clinical trials? How many fold increase CD8 in PB was achieved compared to HD IL-2 IV?

Thanks.

[NY1972]

ACT?+?NKTR-214 achieves long-lasting anti-tumor responses

https://www.nature.com/articles/s41467-019-12901-3

[NY1972]

IO backbone not getting new support beam. IL-2 no help for TIL

Nektar Therapeutics and Bristol Myers Squibb (NYSE: BMY) today announced that based on results from pre-planned analyses of two late-stage clinical studies of bempegaldesleukin (BEMPEG) in combination with Opdivo (nivolumab) in renal cell carcinoma (RCC) and bladder cancer, the companies have jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo. These studies and all other ongoing studies in the program will be discontinued.

[Imokhopeur]

Thx NY!

[NY1972]

Enjoy the very hot bath. No clothes or masks req'd for longs

[Imokhopeur]

I’m in!

[INFINITI]

Time to load up oversold here $$$$

[INFINITI]

Leerink Partners Thinks Genocea Biosciences’ Stock is Going to Recover

Source: TipRanks
Leerink Partners analyst Daina Graybosch maintained a Buy rating on Genocea Biosciences (GNCA – Research Report) yesterday. The company's shares closed last Monday at $0.60, close to its 52-week low of $0.39. According to TipRanks.com, Graybosch 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -15.6% and a 31.9% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Silverback Therapeutics, Werewolf Therapeutics, and Century Therapeutics. Currently, the analyst consensus on Genocea Biosciences is a Strong Buy with an average price target of $5.68, implying an 890.8% upside from current levels. In a report issued on April 10, Robert W.
https://www.tipranks.com/news/blurbs/leerink-partners-thinks-genocea-biosciences-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral

[INFINITI]

Cmon slap that as$$k

[NY1972]

Oversold last week

[INFINITI]

Looks good I’m in price target $9 wow

[PennyPusher786]

Why is this running today?

[Just-Keep-Trying]

GNCA: $9.00 price target by Wainwright; ya might wanna get some at only $0.77.
https://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Genocea+Biosciences+%28GNCA%29+at+Buy+with+%249+Price+Target%2C+Remains+Optimistic+of+GEN-011+Antitumor+Efficacy+and+Durability%2C+Sees+Significant+%22Value-generating+Potential%22/19897573.html

[Just-Keep-Trying]

GNCA: (NEWS) Today's PRICE analysis says GNCA going WAY UP!!
https://www.investorsobserver.com/news/stock-update/what-is-wall-streets-target-price-for-genocea-biosciences-inc-gnca-stock-monday

(MORE NEWS) https://pulse2.com/genocea-biosciences-nasdaq-gnca-stock-why-the-price-surged-over-40-today/

(AND MORE NEWS) https://pennystocks.com/featured/2022/04/11/best-penny-stocks-now-3-watch-hoth-stock-explodes/

[NY1972]

HD lympho results in better chance to shift the body chemistry and disrupt the TME. Higher MCP-1 follows with higher M1 and GEN11 or CAR T to finish off the tumor. No Ab, PD1, Kras ... combos will be a breakthrough. Neural networks no matter the dimensions will never beat cancer

[TheFinalCD]

+50%

[jondoeuk]

Based on the clinical data so far, patients need to be properly conditioned (with LD chemo). As for the future, it may be possible to reduce or eliminate it one day.

[NY1972]

CAR-T efficacy: is conditioning the key?
https://ashpublications.org/blood/article/133/17/1799/275911/CAR-T-efficacy-is-conditioning-the-key

[NY1972]

These findings show that higher serum day 0 MCP-1 and peak IL-7 concentrations, reflecting a more favorable cytokine profile achieved by a subset of patients after high-intensity lymphodepletion, are associated with better PFS after treatment of patients with aggressive NHL with CD19 CAR T cells

[NY1972]

ACT alone with never work

https://ashpublications.org/blood/article/133/17/1876/275916/The-response-to-lymphodepletion-impacts-PFS-in

[jondoeuk]

AACR 2021 https://aacrjournals.org/cancerres/article/81/13_Supplement/2177/668036/Abstract-2177-Tumor-neoantigen-profiling-with https://aacrjournals.org/cancerres/article/81/13_Supplement/1526/667398

SITC 2021 https://jitc.bmj.com/content/9/Suppl_2/A858

AACR 2022

[jondoeuk]

Dr. Jason Westin gave a talk at AACR looking at the product attributes of axi-cel that are associated with efficacy and toxicity. A product enriched with naive T-cells (CCR7+CD45RA+), both CAR+ and CAR-, expressing CD27 and CD28 was associated will all efficacy metrics, including durable responses. So optimising product composition towards this phenotype could improve the outcome for other patients. If so, there are other ways they could build on it.

[NY1972]

044 40 y/o SCLC PD-L1 <1%
• 4 prior tx
• PD-L1 refractory
• Brain mets
• Cy x 2/Flu x 5
• 8 IL-2 doses
• Expected chemotherapy and reduced IL-2 effects
• Delayed low grade neurotox but no ICANS

[NY1972]

ICANS spans a variety of neurologic symptoms such as headache, tremor, speech impairment (e.g., expressive aphasia), delirium, confusion, impaired consciousness (stupor, lethargy, obtundation), and less commonly focal deficits. In our experience, delirum with preserved alertness was the most common presentation of ICANS, accounting for 66% of ICANS cases. In its most severe forms, ICANS can be associated with life-threatening features such as seizures and cerebral edema.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592274/

[NY1972]

Neoantigen IP is worth bread crumb. I am not going anywhere until I see 2B cells + 5 days lymphodepletion + IL-2. 2 pts completed advertized dosing so GNCA will rise up or die in Q3. It is a cancer pt.

[jondoeuk]

Hardly surprising with the dose levels https://www.genocea.com/wp-content/uploads/2022/04/AACR22-GEN-011-Clinical-poster-for-submission.pdf

Now, with higher doses (plus LD chemo and high-dose IL-2), as well as manufacturing process improvements, which yield more neoantigen-specific cells with greater potency, that should start to change. Going forward, they need to continue with the latter and reduce manufacturing times (~16 weeks).

[NY1972]

Homing, planet and CEO need fixing. Sad day for cancer pts. and investors. Next 6 pts will get the 1 B cells + 98% specificity + .... advertized

[murocman]

Responses were not durable. Have to see if they can get to that with higher doses, but will watch from the sidelines.

There will also be dilution ahead.

GLTA,

Murocman

[db7]

and there you have it...........

[db7]

1) HUGE results that are going to make us billionaires OR 2) they really really need to raise money

please be 1...............

[NY1972]

Only bio loud speaking clinical data @AACR.

[NY1972]

My molehill of donut holes is turning into a mountain . No thanks to the IO kols and backbone narrative.

[NY1972]

I will have lots of donut holes for breakfast tomorrow and Friday. I enjoy fishing.

[NY1972]

Gen11 will be given in selected hosp. centers, not for your community oncologists

[NY1972]

She knows the toxic, HLA issues related to CAR T. Best person to tell what GEN11 means to dying pts who run out of options.

[db7]

have to be a registered member to access recordings and slides:

https://coaconference.com/speakers/#keynote

[db7]

from linkedin, would love to find the details of this presentation to see if anything at all to do with our tech


"

Community Oncology Alliance
6,458 followers
2w • 2 weeks ago
Follow

There have been some great new developments in drug treatment for non-small cell lung cancer. Melissa Johnson, MD, of the Sarah Cannon Research Institute taught attendees about these drugs today at #COA2022. Thank you Dr. Johnson!

1 comment
Current selected sort order is Most relevant
Most relevant
See profile for Ravi Bhardwaj Annamraju
Ravi Bhardwaj Annamraju
out of network3rd+
Digital Oncology | Radiology | AI & NLP | Product Mgmt | HL7-FHIR | Startup Ecosystem
2w
Dr Melissa Johnson, your talk on NSCLC & SCLC floored the audience. Spectacular talk !



"

[db7]

"Melissa Johnson, MD
Director, Lung Cancer Research
Dr. Johnson joined Sarah Cannon in 2014 and serves as the director of lung cancer research. Her responsibilities include leading the lung cancer clinical trial portfolio across the Sarah Cannon network. Dr. Johnson continues to work in early phase drug development as well as lead the solid tumor immune effector cellular therapy program at Sarah Cannon. She also currently serves as the chair of the Cancer Committee at TriStar Centennial Medical Center in Nashville, Tenn."

https://sarahcannon.com/about/leadership/melissa-johnson

[db7]

i'm very long here common and calls; just exploring 'every' nook and cranny

g/l

[NY1972]

Market is rational = you can't make cows drink

[db7]

good point...

[NY1972]

Chip will be the first bio CEO to invite an oncologist to a meeting and tell the world his therapy failed miserably. He should win 1 bio oscar for honesty

[db7]

i also have posted that the Friday 'after the close' presentation is 'very' interesting

'but' i think the concern is why poster vs oral 'at' aacr...


g/l to us!

[NY1972]

That is great. Now I know all risks have been priced in. The webinar is the oral presentation. What other bio is holding 1?

[db7]

i see a few posters through various channels with concerns that we are only presenting 'posters' and not 'oral'; your thoughts?

again, i'm not a bio investor and don't know 1/100th of what you guys are referring to in this space BUT the gist of it seems to be it would be an
'oral' presentation if truly good?



thanks!

[db7]

the problem with this is they mention strategic funding 'into 2023' .. seems small and shortsighted VS just saying strategic funding in general(?)

or maybe i'm reading too much into it........

[db7]

'this'... yes please lol

[NY1972]

If GEN11 works and GNCA needs $. GSK will fork over 200 mil per tumor type and 20% sales.

[db7]

i wasn't promoting it; never mentioned it as that's not my style .. no need to play child games

my question was genuine as i'm not much of a biotech investor and i knew that board would have the answer for me


and i do realize i'm playing with fire here as they 'do' have a history of not being shareholder friendly with their raises/dilution..etc.. BUT I love the risk/reward profile AND binary event


g/l!